Pfizer signs exclusive marketing deal with Cipla for 4 brands

Strategic Transactions View source PDF Explain this filing

PFIZER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹5100.00

prior close

₹5092.40

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+1.3%-1.5% vs market

Pharmaceuticals peers, median of 153sector+0.7%-0.9% vs sector

On the reaction day the stock moved 1.5 pts less than Nifty Smallcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.0

15m

-0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+1.3-1.5+0.7-0.9

Next day

+0.6+2.3-1.7+1.3-0.7

-0.5+2.7-3.3+1.4-2.0

-1.1+2.8-3.9+1.4-2.5

-1.0+2.6-3.6+0.7-1.7

-2.8+2.1-4.8+0.0-2.8

-2.6+3.0-5.6+0.7-3.3

15d

-5.2-0.6-4.6-1.0-4.2

-8.4-1.0-7.4-1.8-6.6

-2.0-1.3-0.8-4.0+2.0

-7.5-8.9+1.4-10.2+2.7

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 153Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Pfizer has entered an exclusive 5-year marketing and distribution deal with Cipla for four brands: Corex Dx, Corex LS, Dolonex and Neksium. Cipla will exclusively market and sell these in India while Pfizer continues to manufacture them. No upfront cash exchanged. Deal will reduce Pfizer's field force, with impacted staff supported in career transition. First partnership between the two firms in India. Rationale: Cipla's wider distribution reach to boost availability of these medicines nationwide.

Likely market impact

Mixed impact. Pfizer outsources marketing of legacy brands; near-term workforce restructuring cost. Could improve reach and margins long-term.